BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript
BioCardia, Inc. beats earnings expectations. Reported EPS is $-0.09, expectations were $-0.11.
Source: insidermonkey.com
David Mcclung News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from David Mcclung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In David Mcclung Today - Breaking & Trending Today
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes
SUNNYVALE, Calif., Dec. 18, 2023 -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced...
Source: marketscreener.com
BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K -December 18, 2023 at 07:02 am EST
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes SUNNYVALE, Calif. - December...
Source: marketscreener.com
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval - BioCardia (NASDAQ:BCDA)
SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an
Source: benzinga.com
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules
SUNNYVALE, Calif., Nov. 16, 2023 -- BioCardia, Inc. [Nasdaq: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today...
Source: marketscreener.com